Robert Kramer

“Emergent is a very unique healthcare company, a unique business model. We partner with governments around the world on biodefense, which is an important area, especially in this increasingly dangerous world we live in.”

“As you know, we've been in the press and in the news lately, primarily related to our COVID-19 manufacturing activities. As a result and given that our core business continues to operate pretty much as planned, I'll focus my prepared remarks around the news and let the core business performance speak for itself.”

“Today, I will comment on our financial results for the second quarter and first six months of 2017 compared to last year, walking through the P&L, as well as select elements of our balance sheet.”

“To begin, let me first speak to the concept of financial reporting on continuing operations, which we’re using for the first time. As we reported on August 1st, we successfully completed the spinoff of our Biosciences business into a separately publicly traded company, Aptevo Therapeutics.”

“I'll keep my comments on our quarterly financial performance brief, as our press release and 10-Q to be filed by the end of this week provide the details of the financial metrics for the quarter and year-to-date periods compared to last year.”